Ikegame, Ko
Hikage, Makoto
Fujiya, Keiichi
Kamiya, Satoshi
Tanizawa, Yutaka
Bando, Etsuro
Notsu, Akifumi
Terashima, Masanori
Article History
Accepted: 23 July 2021
First Online: 13 August 2021
Declarations
:
: Masanori Terashima has received personal fees from Taiho Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan, Ono Pharmaceutical Co. Ltd., Bristol Myers Squibb Japan, and Yakult Honsha Co. Ltd. Etsuro Bando has received personal fees from the Eizo Corporation, Kanehara-Shuppan, Terumo Corporation, and Eisai. All other authors declare no conflicts of interest.
: Informed consent was waived by the ethical committee owing to the retrospective nature of the study.
: This study was approved by the institutional review board of the Shizuoka Cancer Center (Approval No. J2020-95-2020-1-2).